

Search query (2): [SP]: 1. a method of evaluating a subject previously diagnosed as having non-aggressive prostate cancer, the method comprising: i) subjecting a blood sample of the subject to one or more immunoassays that measure levels of one or more kallikrein markers selected from: free prostate specific antigen (fpsa), intact prostate specific antigen (ipsa), total prostate specific antigen (tpsa) and human kallikrein 2 (hk2) and ii) determining the probability that a prostate tissue biopsy obtained from the subject would contain detectable aggressive prostate cancer by weighting the measured one or more kallikrein marker levels and at least one clinical factor wherein the at least one clinical factor is selected from a prior negative biopsy or the subject's age. 2. the method of claim 1, wherein if the probability that the prostate tissue biopsy obtained from the subject would contain detectable aggressive prostate cancer is above a threshold level, a follow-up prostate tissue biopsy is obtained from the subject and analyzed to further evaluate presence of aggressive prostate cancer. 3. the method of claim 1, wherein the non-aggressive prostate cancer is associated with a gleason score of 6. 4. the method of claim 1, wherein the aggressive prostate cancer is associated with a gleason score of 7 or more. 5. the method of claim 1, wherein the blood sample is obtained from the subject within 6 months to 12 months from an initial diagnosis of non-aggressive prostate cancer. 6. the method of claim 1 further comprising repeating steps i) and ii) at least once. 7. the method of claim 3 further comprising repeating steps i) and ii) at least once within 6 months to 12 months from first performing steps i) and ii). 8. the method of claim 1 further comprising repeating steps i) and ii) at least twice, wherein the interval between each set of steps i) and ii) is in a range of 6 months to 1 year. 9. the method of claim 1 further comprising repeating steps i) and ii) at least once per year for up to five years. 10. the method of claim 1, wherein the at least one clinical factor is the subject's age. 11. the method of claim 1, wherein determining the probability that a prostate tissue biopsy obtained from the subject would contain detectable aggressive prostate cancer further comprises weighting at least one additional clinical factor, wherein the at least one additional clinical factor is a parameter indicative of the outcome of a digital rectal examination performed on the subject. 12. the method of claim 1, wherein determining the probability that a prostate tissue biopsy obtained from the subject would contain detectable aggressive prostate cancer further comprises weighting at least one additional clinical factor, wherein the at least one additional clinical factor is selected from: number of prostate tissue biopsies performed on the subject to date results of prior prostate tissue biopsies performed on the subject to date occurrence of any negative biopsy since an initial diagnosis of non-aggressive prostate cancer occurrence of any negative biopsy in one-year prior to obtaining the blood sample total number of biopsies since an initial diagnosis of non-aggressive prostate cancer prostate volume on prior biopsy number of positive cores on prior biopsy percent positive cores on prior biopsy cross-sectional area of cancer in biopsy core sections maximum cross-sectional area of cancer in any biopsy core sections psa density rate of subject family history of prostate cancer maximum percent of positive cores from any prior biopsy and maximum number of positive cores from any prior biopsy. 13. the method of claim 1, wherein the probability that a subject has aggressive prostate cancer is further determined by weighting a cubic spline term based on the measured kallikrein marker level(s). 14. a method for determining a probability of an event associated with prostate cancer, the method comprising: receiving, via an input interface, information indicative of levels of one or more kallikrein markers selected from: tpsa, fpsa, ipsa, and hk2 in a blood plasma sample of a subject previously diagnosed as having a non-aggressive prostate cancer receiving, via an input interface, information about at least one clinical factor of the subject evaluating, using at least one processor, a logistic regression model based, at least in part, on the received information to determine a probability of an event associated with prostate cancer in the subject, wherein evaluating the logistic regression model comprises: determining the probability of the event associated with prostate cancer based, at least in part, on the information indicative of levels of one or more of tpsa, fpsa, ipsa, and hk2 and the information about the at least one clinical factor and outputting an indication of the probability of the event associated with prostate cancer, wherein the event associated with prostate cancer is an upgrade from a non-aggressive prostate cancer to an aggressive prostate cancer wherein the at least one clinical factor is selected from a prior negative biopsy or the subject's age. 15. a computer for determining a probability of an event associated with prostate cancer, the computer comprising: an input interface configured to receive information indicative of levels of one or more kallikrein markers selected from: tpsa, fpsa, ipsa, and hk2 in a blood plasma sample of a subject and information about at least one clinical factor of the subject at least one processor programmed to evaluate a logistic regression model based, at least in part, on the received information to determine a probability of an event associated with prostate cancer in the subject, wherein evaluating the logistic regression model comprises: determining the probability of the event associated with prostate cancer based, at least in part, on the information indicative of levels of one or more of tpsa, fpsa, ipsa, and hk2 and the information about the at least one clinical factor and an output interface configured to output an indication of the probability of the event associated with prostate cancer, wherein the event associated with prostate cancer is an upgrade from a non-aggressive prostate cancer to an aggressive prostate cancer wherein the at least one clinical factor is selected from a prior negative biopsy or the subject's age. 16. a system for determining a probability of an event associated with prostate cancer, the system comprising: a) a detector configured to measure levels of one or more kallikrein markers selected from: tpsa, fpsa, ipsa, and hk2 in a blood plasma sample of a subject and b) the computer of claim 15, wherein the computer is in electronic communication with the detector. 17. a computer-readable storage medium encoded with a plurality of instructions that, when executed by a computer, perform a method for determining a probability of an event associated with prostate cancer, wherein the method comprises: evaluating a logistic regression model based, at least in part, on information indicative of levels of one or more kallikrein marker selected from: tpsa, fpsa, ipsa, and hk2 in a blood plasma sample of a subject and information about at least one clinical factor of the subject to determine a probability of an event associated with prostate cancer in the subject, wherein evaluating the logistic regression model comprises: determining the probability of the event associated with prostate cancer based, at least in part, on the information indicative of levels of one or more of tpsa, fpsa, ipsa, and hk2 and the at least one clinical factor and outputting an indication of the probability of the event associated with prostate cancer is an upgrade from a non-aggressive prostate cancer to an aggressive prostate cancer wherein the at least one clinical factor is selected from a prior negative biopsy or the subject's age. 18. the method of claim 14, wherein the method further comprises receiving, via an input interface, information about at least one additional clinical factor, wherein determining the probability of the event associated with prostate cancer is further based on weighting at least one additional clinical factor, and wherein the at least one additional clinical factor is selected from: the subject's age a parameter indicative of the outcome of a digital rectal examination performed on the subject number of prostate tissue biopsies performed on the subject to date results of prior prostate tissue biopsies performed on the subject to date occurrence of any negative biopsy since an initial diagnosis of non-aggressive prostate cancer occurrence of any negative biopsy in one-year prior to obtaining the blood sample total number of biopsies since an initial diagnosis of non-aggressive prostate cancer prostate volume on prior biopsy number of positive cores on prior biopsy percent positive cores on prior biopsy cross-sectional area of cancer in biopsy core sections maximum cross-sectional area of cancer in any biopsy core sections psa density rate of subject family history of prostate cancer maximum percent of positive cores from any prior biopsy and maximum number of positive cores from any prior biopsy. 19. the computer of claim 15, wherein the

Results: 16

1) Family number: 32432093 (US2005282199A)

© PatBase

Title: METHOD TO PREDICT PROSTATE CANCER

Abstract: A method for predicting the probability or risk of prostate cancer is provided.

Classifications:

International (IPC 8-9): A61B19/00 A61B5/20 C12Q1/68 G01N33/48

G01N33/50 G01N33/574 G06F19/00 G06G1/00 (Advanced/Invention);

G06F19/00 (Advanced/Non-invention);

G06G1/00 (Core/Invention);

G06F19/00 (Core/Non-invention)

International (IPC 1-7): C12Q1/68 G01N33/48 G01N33/50 G01N33/574

G06F19/00

CPC: G16H50/70 G01N33/57434 C12Q1/6886 C12Q2600/112

C12Q2600/118 C12Q2600/136 G06G1/001

European: C12Q1/68M6B G01N33/574C14 G01N33/68V2 G06F19/00M3S

G06G1/00B1 M12Q600/112 M12Q600/118 S06F19/34J

US: 435/6 435/6.14 435/6.140P 435/6P 435/7.230S 702/19

702/19S




FIG. 1

Family:

Publication number	Publication date	Application number	Application date
AU2005242724 AA	20051124	AU20050242724	20050511
CA2564208 AA	20061025	CA20052564208	20050511
EP1747466 A2	20070131	EP20050750092	20050511
US2005282199 AA	20051222	US20050126945	20050511
WO05111625 A2	20051124	WO2005US16582	20050511
WO05111625 A3	20060316	WO2005US16582	20050511

Priority:

US20040569805P 20040511 US20050126945 20050511 WO2005US16582 20050511

Probable Assignee: BAYLOR COLLEGE OF MEDICINE

Assignee(s): (std): BAYLOR COLLEGE MEDICINE ; KATTAN MICHAEL ; SLAWIN KEVIN M ; SLOAN KETTERING INST CANCER

Assignee(s): MEMORIAL SLOAN KETTERING CANCER CENTER ; BAYLOR COLLEGE OF MEDICINE

Inventor(s): (std): SLAWIN KEVIN M ; KATTAN MICHAEL

Inventor(s): MICHAEL KATTAN ; KEVIN M SLAWIN

Agent(s): PHILLIPS ORMONDE FITZPATRICK; SIM AND MCBURNEY; SCHWEGMAN LUNDBERG WOESSNER AND KLUTH

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GW HR HU ID IE IL IN IS IT JP KE KG KM KP KR KZ LC LI LK LR LS LT LU LV MA MC MD MG MK ML MN MR MW MX MZ NA NE NG NI NL NO NZ OM PG PH PL PT RO RU SC SD SE SG SI SK SL SM SN SY SZ TD TG TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

2) Family number: 61048154 (US2018273634A)

© PatBase

Title: ANTIBODY POLYPEPTIDES AND USES THEREOF

Abstract: The present invention provides antibody polypeptides with binding specificity for prostate specific antigen (PSA), wherein the antibody polypeptide comprises (a) a heavy chain variable region comprising the amino acid sequences of SEQ ID NO:1 and SEQ ID NO:2 and SEQ ID NO:3 and/or (b) a light chain variable region comprising the amino acid sequences of SEQ ID NO:4 and SEQ ID NO:5 and SEQ ID NO:6, and wherein the heavy chain variable region and light chain variable region comprise framework amino acid sequences from one or more human antibodies. The invention further provides use of said antibody polypeptides in the diagnosis and treatment of prostate cancer

Classifications:

International (IPC 8-9): A61K A61K39/395 A61K47/54 A61K47/60
A61K47/61 A61K47/64 A61K47/68 A61K49/16 A61K49/22 A61K51/10
A61P13/08 A61P35/00 C07K C07K16/18 C07K16/30 C12N1/15 C12N1/19
C12N1/21 C12N15/13 C12N15/67 C12N5/10 C12P21/08 C12Q1/06
G01N33/574 (Advanced/Invention);
C07K (Subclass/Invention)

International (IPC 1-7): A61K39/395 A61K49/16 A61K51/10 C07K16/30
CPC: A61K39/395 A61K51/1072 A61K51/1096 A61K2039/505 A61P35/00
C07K16/3069 C07K2317/24 C07K2317/55 C07K2317/565 C07K2317/92
C07K2317/94 A61K47/6803 A61K47/6869 C07K2317/21 C07K2317/54
C07K2317/56 C07K2317/567 C07K2317/569 C07K2317/622
C07K2317/624 G01N33/57434

US: 1/1 424/1.49


JP F-Term: 2G045 4B024 4B063 4B063/QA01 4B063/QA14 4B063/QA18
4B063/QA19 4B063/QQ02 4B063/QQ03 4B063/QQ79 4B063/QR48
4B063/QS28 4B063/QS33 4B063/QX01 4B063/QX07 4B064 4B064/AG26
4B064/AG27 4B064/CA02 4B064/CA05 4B064/CA06 4B064/CA08
4B064/CA10 4B064/CA19 4B064/CC24 4B064/DA01 4B064/DA05

4B064/DA13 4B064/DA14 4B065 4B065/AA01 4B065/AA57 4B065/AA72
 4B065/AA83 4B065/AA90 4B065/AA93 4B065/AB01 4B065/AC14
 4B065/BA02 4B065/BD22 4B065/BD25 4B065/BD29 4B065/BD38
 4B065/BD39 4B065/CA25 4B065/CA44 4B065/CA46 4C076 4C076/CC27
 4C076/DD41 4C076/EE23 4C076/EE30 4C076/EE41 4C076/EE59
 4C076/FF31 4C084 4C084/AA12 4C084/NA14 4C084/ZA81 4C084/ZB26
 4C085 4C085/AA14 4C085/AA16 4C085/AA26 4C085/BB36 4C085/BB41
 4C085/BB43 4C085/CC23 4C085/DD62 4C085/EE01 4C085/EE03
 4C085/HH03 4C085/HH07 4C085/HH09 4C085/KA04 4C085/KA05
 4C085/KA09 4C085/KA28 4C085/KA29 4C085/KB05 4C085/KB07
 4C085/KB08 4C085/KB09 4C085/KB10 4C085/KB11 4C085/KB12
 4C085/KB15 4C085/KB18 4C201 4H045 4H045/AA10 4H045/AA11
 4H045/AA20 4H045/AA30 4H045/BA10 4H045/BA51 4H045/BA53
 4H045/BA55 4H045/BA57 4H045/BA71 4H045/BA72 4H045/CA40
 4H045/DA75 4H045/DA76 4H045/DA86 4H045/EA20 4H045/EA50
 4H045/EA51 4H045/FA74

JP F-Index: A61K39/395/N A61K47/54 A61K47/60 A61K47/61
 A61K47/64 A61K49/06 A61K49/08 A61K49/10 A61K49/12 A61K49/16
 A61K49/22 A61K51/00/100 A61K51/00/200 A61K51/02/200
 A61K51/04/200 A61K51/10/100 A61K51/10/200 A61P13/08 A61P35/00
 C07K16/18/ZNA C12N1/15 C12N1/19 C12N1/21 C12N15/13
 C12N15/67/Z C12N5/10 C12P21/08 C12Q1/06 G01N33/574/D

JP Facet: ZNA

PatBase - US2018273634_AA
 FIGURE 1



Family:

Publication number	Publication date	Application number	Application date
AU2016334715 AA	20180412	AU20160334715	20161004
BR112018006820 A2	20181023	BR20181106820	20161004
CA2998818 AA	20180315	CA20162998818	20161004
CN108136013 A	20180608	CN201680059166	20161004
EP3359189 A1	20180815	EP20160778330	20161004
GB201517550 A0	20151118	GB20150017550	20151005
GB201519105 A0	20151216	GB20150019105	20151029
HK1258674 A1	20191115	HK20190101041	20190121
IL258189 A0	20180531	IL20160258189	20161004
JP2018531045 T2	20181025	JP20180536343T	20161004
KR20180053756 A	20180523	KR20187012299	20161004
MX2018004071 A1	20181109	MX20180004071	20161004
RU2018115734 A	20191107	RU20180115734	20161004
RU2018115734 A3	20200327	RU20180115734	20161004
US2018273634 AA	20180927	US20160761260	20161004
WO17060247 A1	20170413	WO2016EP73684	20161004

Priority:

GB20150017550 20151005 GB20150019105 20151029 WO2016EP73684 20161004
 RU20180115734 20161004

Probable Assignee: FREDAX AB

Assignee(s): (std): FREDAX AB

Assignee(s): LAMMINMAKI URPO JUHANI ; TRAN AMANDA THUY ; MALMBORG HAGER CECILIA ANN CHRISTIN ;
 SJOESTROM KJELL ; STRAND SVEN ERIK ; AXELSSON ANDERS ; FREDAX AB

Inventor(s): (std): URPO JUHANI LAMMINMAEKI ; SVEN ERIK STRAND ; KJELL SJOESTROM ; CECILIA ANN CHRISTIN
 MALMBORG HAGER ; ANDERS AXELSSON ; AMANDA THUY TRAN ; LAMMINMAEKI URPO JUHANI ; MALMBORG
 HAGER CECILIA ANN CHRISTIN ; AXELSSON ANDERS ; STRAND SVEN ERIK ; TRAN AMANDA THUY ;
 SJOESTROM KJELL ; SJOESTROM KJELL ; LAMMINMAKI URPO JUHANI

Inventor(s): LAMMINMAKI URPO YUKHANI ; SHESTREM CHELL ; MALMBORG KHAGER SESILIYA ANNA KRISTINA ;
 AKSELSSON ANDERS ; TRAN AMANDA TUJ

Agent(s): DAVIES COLLISON CAVE PTY LTD; GOWLING WLG CANADA LLP; POTTER CLARKSON LLP; WENPING AND
 CO; SOYUZPATENT OOO; SMITH STEPHEN EDWARD

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BN BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU
 CY CZ DE DJ DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL
 IN IR IS IT JP KE KG KM KN KP KR KW KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR
 MT MW MX MY MZ NA NE NG NI NL NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SI SK
 SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

3) Family number: 14126245 (US2004101914A)

© PatBase

Title: NOVEL ANTIBODY, IMMUNOASSAY AND METHOD FOR PROSTATE CANCER DETECTION

Abstract: This invention concerns an antibody wherein said antibody does bind with high affinity to human single-chain intact, i.e. not internally cleaved, mature and/or zymogen forms of prostate specific antigen (SCINT PSA). The antibody, obtainable through immunization with an uncleaved form of PSA and selected by its differential reactivity with the intact and internally cleaved forms, does not bind to a nicked PSA (PSA-N), wherein said PSA-N has been formed by internal peptide bond cleavage(s) of SCINT PSA resulting in two-chain or multi-chain PSA. This invention further concerns an immunoassay and a method for differentiating patients with cancer of the prostate (PCa) from patients with benign prostatic hyperplasia (BPH) and/or healthy male subjects without PCa, patients with aggressive PCa from patients with indolent PCa and/or patients with clinically localized and/or organ confined PCa from patients with extraprostatic extension of PCa and/or PCa with metastatic spread to lymph nodes or bone marrow using said antibody.

Classifications:

International (IPC 8-9): C07K16/00 C07K16/18 C07K16/40 C07K17/00 C12N9/64 C12P21/08 C12Q1/02 G01N33/00 G01N33/53 G01N33/531 G01N33/543 G01N33/573 G01N33/574 (Advanced/Invention); C12N15/02 C12P21/08 (Advanced/Non-invention); C07K16/18 C07K16/40 C12N9/64 G01N33/531 G01N33/543 G01N33/574 (Core/Invention)

International (IPC 1-7): C07K C07K14/47 C07K16/18 C07K16/40 C12N9/64 G01N33/531 G01N33/543 G01N33/573 G01N33/574


CPC: C12N9/6445 C07K16/40 G01N33/57434

European: C07K16/40 C12N9/64F21K G01N33/574C14 M07K203/00

US: 435/7.1 435/7.23 435/7.230P 435/7.92 530/35 530/350 530/350S 530/388.1 530/388.25 530/388.26 530/388.260S 530/388.8 530/388.85 530/391.1 530/391.3

JP F-Term: 2G045 4B024 4B024/AA11 4B024/BA36 4B024/BA54 4B024/GA03 4B024/HA03 4B024/HA15 4B063 4B063/QA18 4B063/QA19 4B063/QQ02 4B063/QQ08 4B063/QQ79 4B063/QR48 4B063/QR72 4B063/QR77 4B063/QS33 4B063/QX01 4B064 4B064/AG27 4B064/BJ12 4B064/CA10 4B064/CA20 4B064/CC15 4B064/CC24 4B064/DA14 4H045 4H045/AA11 4H045/CA40 4H045/DA76 4H045/EA51

JP F-Index: C07K16/18 C07K16/40 C12N15/00/C C12P21/08 C12Q1/02 G01N33/53/V G01N33/531/A G01N33/543/515/D G01N33/574/A



Family:

Publication number	Publication date	Application number	Application date
AT425460 E	20090315	AT20010972118T	20010926
AU2001291911 AA	20020408	AU20010291911	20010926
AU200191911 A1	20020408	AU20010091911	20010926
AU200191911 A5	20020408	AU20010091911	20010926
DE60137949 D1	20090423	DE20016037949	20010926
EP1320756 A1	20030625	EP20010972118	20010926
EP1320756 B1	20090311	EP20010972118	20010926
ES2322432 T3	20090622	ES20010972118T	20010926
FI20002127 A0	20000927	FI20000002127	20000927
JP2004509934 T2	20040402	JP20020530851T	20010926
JP5254517 B2	20130807	JP20020530851T	20010926
US2004101914 AA	20040527	US20030381132	20030721
US7872104 BB	20110118	US20010381132	20010926
WO0227323 A1	20020404	WO2001FI00834	20010926

Priority:

FI20000002127 20000927 WO2001FI00834 20010926

Probable Assignee: ARCTIC PARTNERS OY AB

Assignee(s): (std): ARCTIC PARTNERS OY AB ; ARTIC PARTNERS OY AB ; LILJA HANS ; PETERSSON KIM ; LOEVGREN TIMO ; NIEMELAE PAULIINA ; LOVGREN TIMO ; NIEMELA PAULIINA

Inventor(s): (std): PETERSSON KIM ; LILJA HANS ; LOVGREN TIMO ; NIEMELA PAULIINA ; LOEVGREN TIMO ; NIEMELAE PAULIINA ; NURMIKKO PAULIINA

Inventor(s): NIEMELAE PAULIINA ; KIM PETERSSON ; TIMO LOVGREN ; PAULIINA NIEMELA ; HANS LILJA

Agent(s): MASKULA SILLA MARJATTA ET AL; AKIYAMA FUMIO; ROTHWELL FIGG ERNST AND MANBECK PC

Designated states: AE AG AL AM AT AU AZ BA BB BE BF BG BJ BR BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ DE DK DM DZ EC EE ES FI FR GA GB GD GE GH GM GN GQ GR GW HR HU ID IE IL IN IS IT JP KE KG KP KR KZ LC LI LK LR LS LT LU LV MA MC MD MG MK ML MN MR MW MX MZ NE NL NO NZ PH PL PT RO RU SD SE SG SI SK SL SN SZ TD TG TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

4) Family number: 49769289 (US2011253224A)

© PatBase

Title: FEEDBACK CONTROL IN MICROFLUIDIC SYSTEMS

Abstract: Systems and methods for controlling fluids in microfluidic systems are generally described. In some embodiments, control of fluids involves the use of feedback from one or more processes or events taking place in the microfluidic system. For instance, a detector may detect one or more fluids at a measurement zone of a microfluidic system and one or more signals, or a pattern of signals, may be generated corresponding to the fluid(s). In some cases, the signal or pattern of signals may correspond to an intensity, a duration, a position in time relative to a second position in time or relative to another process, and/or an average time period between events. Using this data, a control system may determine whether to modulate subsequent fluid flow in the microfluidic system. In some embodiments, these and other methods can be used to conduct quality control to determine abnormalities in operation of the microfluidic system.

Classifications:

International (IPC 8-9): B01L B01L3/00 B81B1/00 B81B7/00 C12M1/34

F17D3/00 G01F1/00 G01N1/10 G01N15/14 G01N21/00 G01N21/05
G01N21/17 G01N21/59 G01N21/64 G01N21/76 G01N21/77 G01N33/48
G01N33/53 G01N33/543 G01N33/574 G01N35/00 G01N35/02 G01N35/08
G01N37/00 (Advanced/Invention);
B01L7/00 (Advanced/Non-invention);
B01L3/00 G01F1/00 G01N35/00 (Core/Invention);
B01L C12M G01F G01N (Subclass/Invention)

International (IPC 1-7): B01L3/00


CPC: B01L7/00 G01N35/00 G01N35/00732 G01N2035/00237
G01N2035/00465 G01N2035/00752 B01L3/5027 B01L3/502715
B01L3/50273 B01L2200/025 B01L2200/027 B01L2200/028
B01L2200/0673 B01L2200/146 B01L2200/147 B01L2300/027
B01L2300/1827 B01L2300/1894 B01L2400/0475 B01L7/52 B01L2200/026
B01L2200/0684 B01L2200/143 B01L2300/021 B01L2300/0816
B01L2400/0666 B01L3/502746 G01N21/59 Y10T137/0324 Y10T436/12
B01L3/502738 B01L2300/023 B01L2300/04 B01L2300/0654
B01L2300/0867 B01L2300/12 B01L2300/14 B01L2300/16 B01L2300/168
B01L2400/049 B01L2400/082 G01N21/05 G01N21/64 G01N21/76
G01N33/54313 G01N33/54366 G01N33/57434 G01N2201/02
G01N2201/0612 G01N2201/062 G01N2201/0621 G01N2201/0697
G01N2333/96433

European: B01L3/5027 B01L3/5027B L01L200/02C L01L200/02D
L01L200/02D2 L01L200/02E L01L200/06K L01L200/06M L01L200/14C
L01L200/14C4 L01L200/14C6 L01L300/02A L01L300/02D4 L01L300/08B4 L01L300/18A8 L01L300/18J L01L400/04M
L01L400/06M12 L01L7/52

US: 1/1 137/2 137/2P 422/502 422/505 422/68.1 422/82.05 422/82.08 422/82.09 435/288.7 435/288.700S 435/29 435/3 435/5
435/7.1 435/7.100P 436/164 436/172 436/501 436/55 700/266

JP F-Term: 2G058 2G058/GA06 2G058/GB03 2G058/BB02 2G058/BB09 2G058/BB15 2G058/CC08 2G058/DA07 2G058/EA14
2G058/GA02 2G058/GA08 2G058/GC01 2G058/GD06 2G058/AA09 2G058/CC11 2G058/EA16 2G058/GC02 2G058/GC05
2G058/AA05 2G058/BB10 2G058/BB14 2G058/BB24 2G058/BB26 2G058/DA01 2G058/DA09 2G058/EC03 2G058/EC05
2G058/EC07 2G058/FA07 2G058/FB09 2G058/FB12 2G058/GA01

JP F-Index: G01N35/00/F G01N35/08/A G01N37/00/101 G01N35/02/C G01N35/02/G G01N35/00/B G01N35/00/E G01N35/08/D



Family:

Publication number	Publication date	Application number	Application date
AU2011239534 AA	20121115	AU20110239534	20110415
AU2011239534 AA	20111020	AU20110239534	20110415
AU2011239534 AA	20111020	AU20110239534	20110415
AU2011239534 BB	20150122	AU20110239534	20110415
AU2011239538 AA	20111020	AU20110239538	20110415
AU2011239538 BB	20141023	AU20110239538	20110415
AU2013204955 AA	20130516	AU20130204955	20130412
AU2013204955 BB	20150122	AU20130204955	20130412
AU2013204955 CA	20171130	AU20130204955	20130412
AU2015202055 AA	20150514	AU20150202055	20150422
AU2015202055 BB	20170720	AU20150202055	20150422
BR112012026366 A2	20171010	BR20121126366	20110415
BR112012026406 A2	20160802	BR20121126406	20110415
CA2795211 AA	20121001	CA20112795211	20110415
CA2795211 C	20181106	CA20112795211	20110415
CA2795215 AA	20121001	CA20112795215	20110415
CA2795215 C	20181106	CA20112795215	20110415
CA3016653 AA	20111020	CA20113016653	20110415
CA3016967 AA	20111020	CA20113016967	20110415
CL2012002889 A1	20130809	CL20120002889	20121016
CL2012002890 A1	20130125	CL20120002890	20121016
CL52058 B	20160219	CL20120002889	20121016
CL53683 B	20161230	CL20120002890	20121016
CN102939160 A	20130220	CN201180029599	20110415
CN102939160 B	20161012	CN201180029599	20110415
CN102971076 A	20130313	CN201180029612	20110415
CN102971076 B	20151125	CN201180029612	20110415
CN105381825 A	20160309	CN201510671767	20110415
CN107102156 A	20170829	CN201610849312	20110415
CO6630192 A2	20130301	CO20120207302	20121115
CO6640223 A2	20130322	CO20120207307	20121115
CO6640223 A2	20130322	CO20140053204	20121115
CO6640223 A2	20130322	CO20120207307	20121115
EA022356 B1	20151230	EA20120001419	20110415
EA023941 B1	20160729	EA20120001420	20110415
EA201201419 A1	20130430	EA20120001419	20110415
EA201201420 A1	20130228	EA20120001420	20110415
EP2558202 A1	20130220	EP20110716151	20110415
EP2558203 A1	20130220	EP20110716152	20110415
IL222456 A0	20130101	IL20110222456	20110415
IL222456 A1	20170831	IL20110222456	20110415
IL222461 A0	20130101	IL20110222461	20110415
IL222461 A1	20170430	IL20110222461	20110415
IL243824 A0	20160421	IL20110243824	20110415
IL243824 A1	20180531	IL20110243824	20110415
JP2013525762 T2	20130620	JP20130505175T	20110415
JP2013525763 T2	20130620	JP20130505178T	20110415

JP2016218074 A2	20161222	JP20160139224	20160714
JP2018200323 A2	20181220	JP20180163371	20180831
JP6104793 B2	20170329	JP20130505175T	20110415
JP6204190 B2	20170927	JP20130505178T	20110415
MX2012012066 A1	20121217	MX20120012066	20110415
MX2012012067 A1	20121217	MX20120012067	20110415
MX363916 B	20190405	MX20140015001	20110415
PE07992013 A1	20130710	PE20120002025	20110415
PE08032013 A1	20130710	PE20120002032	20110415
PE20130799 A1	20130710	PE20120002025	20110415
PE20130803 A1	20130710	PE20120002032	20110415
UA109132 C2	20150727	UA20120012934	20110415
UA110791 C2	20160225	UA20120012930	20110415
UA115313 C2	20171025	UA20140002764	20110415
US2011253224 AA	20111020	US20110088112	20110415
US2011256551 AA	20111020	US20110088102	20110415
US2013224075 AA	20130829	US20130849084	20130322
US2014038166 AA	20140206	US20130044247	20131002
US2014234180 AA	20140821	US20140266894	20140501
US2015086997 AA	20150326	US20140554205	20141126
US2015343443 AA	20151203	US20150803594	20150720
US2017239656 AA	20170824	US20170588548	20170505
US2018236448 AA	20180823	US20180957023	20180419
US2020070164 AA	20200305	US20190564268	20190909
US8580569 BB	20131112	US20110088112	20110415
US8765062 BB	20140701	US20130849084	20130322
US8932523 BB	20150113	US20110088102	20110415
US9116124 BB	20150825	US20130044247	20131002
US9643182 BB	20170509	US20140554205	20141126
US9682376 BB	20170620	US20140266894	20140501
US9981266 BB	20180529	US20150803594	20150720
US10456784 BB	20191029	US20170588548	20170505
WO11130625 A1	20111020	WO2011US32680	20110415
WO11130629 A1	20111020	WO2011US32685	20110415

Priority:

US20100325023P	20100416	US20100325044P	20100416	US20100363002P	20100709
AU20110239538	20110415	CA20112795211	20110415	CA20112795215	20110415
CN201180029612	20110415	JP20130505178T	20110415	CN201180029599	20110415
UA20120012934	20110415	JP20160139224	20110415	US20110088112	20110415
US20110088102	20110415	WO2011US32680	20110415	WO2011US32685	20110415
US20120325023P	20121016	US20130849084	20130322	AU20130204955	20130412
US20130044247	20131002	US20140266894	20140501	US20140554205	20141126
AU20150202055	20150422	US20150803594	20150720	JP20160139224	20160714
US20170588548	20170505	US20180957023	20180419	JP20180163371	20180831
CA20182795211	20180911	CA20182795215	20180913	US20190564268	20190909

Probable Assignee: OPKO DIAGNOSTICS LLC

Assignee(s): (std): LINDER VINCENT ; STEINMILLER DAVID ; TAYLOR JASON ; OPKO DIAGNOSTICS LLC ; CLAROS DIAGNOSTICS INC

Assignee(s): CLAROS DIAGNOSTICS LLC ; CLAROS MERGER SUBSIDIARY LLC UNDER NAME OF CLAROS ; CLAROS MERGER SUBSIDIARY LLC UNDER NAME OF CLAROS DIAGNOSTICS LLC

Inventor(s): (std): LINDER VINCEN ; DAVID STEINMILLER ; JASON TAYLOR ; VINCENT LINDER ; TAYLOR JASON ; STEINMILLER DAVID ; LINDER VINCENT

Agent(s): SHELSTON IP; SHELSTON IP PTY LTD; CASSAN MACLEAN; CASSAN MACLEAN IP AGENCY INC; SARGENT AND KRAHN; LUZ CLEMENCIA DE PAEZ; HOFFMANN EITLE; SANFORD TCOLB AND CO; KAWABATA JUNICHI; YAMADA TAKUJI; TANAKA MITSUO; WOLF GREENFIELD AND SACKS PC; OYER TIMOTHY J

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PE PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

5) Family number: 76609374 (WO19221930A1)

© PatBase

Title: METHODS FOR DETECTING PROSTATE CANCER PATHOLOGY ASSOCIATED WITH ADVERSE OUTCOMES


Abstract: Aspects of the disclosure relate to improved methods and systems for predicting prostate cancer pathology associated with adverse outcomes in patients determined to a primary Gleason Grade of 3.

Classifications:

International (IPC 8-9): G01N33/574 G01N33/68 G16H50/20

G16H70/60 (Advanced/Invention)

CPC: G16H20/00 G16H50/30 G16H50/70 G01N33/574 G01N33/68

**Family:**

Publication number	Publication date	Application number	Application date
WO19221930 A1	20191121	WO2019US30555	20190503

Priority:

US20180672336P 20180516

Probable Assignee: OPKO DIAGNOSTICS LLC**Assignee(s):** (std): OPKO DIAGNOSTICS LLC**Inventor(s):** (std): DONG YAN ; OKRONGLY DAVID**Agent(s):** LEE JESSAMINE N ET AL

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BN BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DJ DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IR IS IT JO JP KE KG KH KM KN KP KR KW KZ LA LC LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

6) Family number: 48433401 (WO11027308A1)

© PatBase


Title: NOVEL TUMOR MARKERS

Abstract: The present invention relates to a tumor marker or group of tumor markers associated with the progression of a neoplastic disease from a less progressed stage to a more progressed stage, wherein the expression of the tumor markers is modified when comparing the expression in the less progressed stage and in the more progressed stage. The present invention further relates to a composition for diagnosing, detecting, graduating, monitoring or prognosticating a neoplastic disease associated with a progression from a less progressed cancer stage to a more progressed cancer stage comprising affinity ligands for the expression products of the tumor markers, to corresponding methods, and to the use of said tumor markers for detecting, diagnosing, graduating, monitoring or prognosticating a neoplastic disease associated with a progression from a less progressed cancer stage to a more progressed cancer stage. The present invention further relates to a corresponding immunoassay, to a method of identifying an individual for eligibility for a neoplastic disease therapy, as well as to a pharmaceutical composition based on the inhibition and/or activation of the expression of said tumor markers.

Classifications:**International (IPC 8-9):** G01N33/574 (Advanced/Invention)

CPC: A61K39/00 C12Q1/6886 C12Q2600/118 G01N2800/50
G01N2800/52 G01N2800/60 C12Q2600/106 C12Q2600/112 G01N33/574
G01N33/57419 G01N33/57423 A61K38/00 A61K39/0011 A61K2039/515
A61K2039/53 G01N33/57484 G01N33/57434 G01N2800/56

European: A61K39/00D6 C12Q1/68M6B G01N33/574 G01N33/574C14
G01N33/574C6 G01N33/574C8 G01N33/574V K61K38/00 K61K39/00
K61K39/515 K61K39/53 M12Q600/106 M12Q600/112 M12Q600/118
S01N800/50 S01N800/52 S01N800/56 S01N800/60



Family:

Publication number	Publication date	Application number	Application date
EP2295977 A1	20110316	EP20090179125	20091214
EP2473853 A1	20120711	EP20100760034	20100902
WO11027308 A1	20110310	WO2010IB53940	20100902
WO11027308 A8	20111215	WO2010IB53940	20100902
WO11027310 A1	20110310	WO2010IB53942	20100902
WO11027310 A8	20111208	WO2010IB53942	20100902
WO11027311 A2	20110310	WO2010IB53943	20100902
WO11027311 A3	20110512	WO2010IB53943	20100902
WO11027312 A1	20110310	WO2010IB53944	20100902
WO11073896 A1	20110623	WO2010IB55796	20101214
WO11073896 A8	20111215	WO2010IB55796	20101214
WO11073901 A1	20110623	WO2010IB55801	20101214
WO11073901 A8	20111208	WO2010IB55801	20101214
WO11073903 A1	20110623	WO2010IB55803	20101214
WO11073905 A1	20110623	WO2010IB55805	20101214
WO11073905 A8	20111208	WO2010IB55805	20101214

Priority:

EP20090169423	20090903	EP20090169424	20090903	EP20090169428	20090903
EP20090169426	20090903	EP20090169427	20090903	EP20090179125	20091214
EP20100155369	20100303	EP20100165039	20100607	EP20100165040	20100607
EP20100165043	20100607	WO2010IB53944	20100902	EP20100760034	20100902
WO2010IB55796	20101214				

Probable Assignee: KONINKL PHILIPS ELECTRONICS NV

Assignee(s): (std): HOFFMANN RALF ; HULSEN TIM ; KONINKL PHILIPS ELECTRONICS NV ; ROMIJN EDWIN P ; VISSER HUGO M ; VISSER HUGO MATTHIEU ; ROMIJN EDWIN PETER ; WAANDERS LEONIE ; MERKLE DENNIS

Assignee(s): PHILIPS ELECTRONICS KONINKLL NV ; KONINKLIJKE PHILIPS ELECTRONICS N V

Inventor(s): (std): HOFFMANN RALF ; HULSEN TIM ; ROMIJN EDWIN P ; VISSER HUGO M ; WAANDERS LEONIE ; ROMIJN EDWIN PETER ; VISSER HUGO MATTHIEU ; MERKLE DENNIS

Inventor(s): THE DESIGNATION OF THE INVENTOR HAS NOT YET...

Agent(s): JUNGEN CARMEN; DAMEN DANIEL MARTIJN; KROEZE JOHN ET AL

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PE PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

7) Family number: 42521409 (US2013224209A)

© PatBase

Title: METHODS FOR DIAGNOSING AND TREATING PROSTATE AND LUNG CANCER

Abstract: Methods for detecting and treating prostate and lung cancer are disclosed In practicing the method, a subject sample is assayed for GPR110 protein or its RNA transcript, and the GPR110 or transcript level observed is used in determining whether the subject has an elevated GPR110 level associated with prostate or lung cancer. Patients with such elevated levels may be treated, in accordance with the invention, with a variety of GPR110 related immunotherapy agents.

Classifications:

International (IPC 8-9): A61K39/395 A61P35/00 C12N15/09 C12Q1/68 G01N33/53 G01N33/534 G01N33/543 G01N33/574

G01N33/68 (Advanced/Invention);

C07K14/705 G01N33/574 (Advanced/Non-invention);

A61K39/395 A61P35/00 C12N15/09 C12Q1/68 G01N33/53 G01N33/534

G01N33/543 G01N33/574 (Core/Invention)

International (IPC 1-7): C12Q1/68

CPC: G01N33/6893 C12Q2600/156 C12Q2600/158 A61P35/00

C12Q1/6886 G01N33/57423 G01N33/57434 G01N2333/726

European: C12Q1/68M6B G01N33/574C14 G01N33/574C8 S01N333/72B


US: 424/139.1 435/287.2 435/6.12 435/7.23

JP F-Term: 2G045 4B024 4B024/AA12 4B024/CA11 4B024/HA14 4B063

4B063/QA18 4B063/QA19 4B063/QQ03 4B063/QQ08 4B063/QQ52

4B063/QR07 4B063/QR08 4B063/QR32 4B063/QR56 4B063/QR62

4B063/QS25 4B063/QS34 4B063/QX02 4C085 4C085/AA13 4C085/AA14
 4C085/CC22 4C085/CC23 4C201
JP F-Index: A61K39/395/E A61K39/395/T A61P35/00 C12N15/00/A
 C12Q1/68/A C12Q1/6886/C C12Q1/6886/Z G01N33/534
 G01N33/543/521 G01N33/543/541/Z G01N33/543/575
 G01N33/574/ZNA/A
JP Facet: ZNA



Family:

Publication number	Publication date	Application number	Application date
AU2008251877 AA	20081120	AU20080251877	20080508
AU2008251877 AB	20100204	AU20080251877	20080508
AU2008251877 AI	20100121	AU20080251877	20080508
CA2686954 AA	20091109	CA20082686954	20080508
CN101918836 A	20101215	CN200880023852	20080508
CN101918836 B	20140430	CN200880023852	20080508
DE602008028992 D1	20140130	DE200860028992T	20080508
EP2156184 A2	20100224	EP20080754314	20080508
EP2156184 A4	20100721	EP20080754314	20080508
EP2156184 B1	20131127	EP20080754314	20080508
IN07984DN2009 A	20100709	IN2009DN07984	20091207
JP2010528261 T2	20100819	JP20100507474T	20080508
US2013224209 AA	20130829	US20130746180	20130121
WO08140774 A2	20081120	WO2008US05983	20080508
WO08140774 A3	20090115	WO2008US05983	20080508
WO08140774 A9	20100211	WO2008US05983	20080508

Priority:

US20070916719P 20070508 EP20080754314 20080508 WO2008US05983 20080508
 US20110218796 20110826 US20120421518 20120315 US20130746180 20130121

Probable Assignee: PICOBELLA LLC

Assignee(s): (std) PICOBELLA LLC ; WABL MATTHIAS ; WANG BRUCE

Assignee(s): PICOBELLA LLC BURLINGAME ; PICO BELLA LLC

Inventor(s): (std) WABL MATTHIAS ; WANG BRUCE ; BRUCE WANG ; MATTHIAS WABL

Inventor(s): WABL MATTHIAS SAN FRANCISCO ; WANG BRUCE MOUNTAIN VIEW

Agent(s): EF WELLINGTON AND CO; E F WELLINGTON AND CO; OSLER HOSKIN AND HARCOURT LLP; MUELLER
 FOTTNER STEINECKE RECHTSANWALTS U PATENTANWALTSPARTNERSCHAFT MBB; SMAGGASGALE GILLIAN
 HELEN; MURRAY ADRIAN DCOLIGNY; DEHLINGER PETER J ET AL

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CM CN CO CR CU CY CZ
 DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP
 KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ
 NA NE NG NI NL NO NZ OM PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN SV SY SZ TD TG TJ TM TN

8) Family number: 8535487 (US5599677A)

© PatBase

Title: IMMUNOASSAYS FOR PROSTATE SPECIFIC ANTIGEN

Abstract: The present invention relates to the field of cancer immunoassay. Specifically, a new immunoassay method for prostate specific antigen (PSA) is presented. Also presented is a complex which resembles a complex of PSA and alpha - antichymotrypsin (ACT) that can be used as a calibrator or control in an immunoassay for PSA. Further presented is a method for fractionating polyclonal antibodies, to PSA, into those which bind epitopes that are masked by the binding of PSA to ACT and those which do not bind such epitopes.

Classifications:

International (IPC 8-9): A61K39/395 C07K16/00 C07K16/18 C07K19/00 G01N33/53 G01N33/543 G01N33/564 G01N33/566 G01N33/573 G01N33/574 G01N33/577 G01N33/68 (Advanced/Invention); A61K39/395 C07K16/18 C07K19/00 G01N33/53 G01N33/543 G01N33/566 (Advanced/Non-invention); A61K39/395 C07K16/00 C07K16/18 C07K19/00 G01N33/53 G01N33/543 G01N33/564 G01N33/566 G01N33/573 G01N33/574 G01N33/577 G01N33/68 (Core/Invention)

International (IPC 1-7): A61K39/395 C07K16/18 C07K19/00 G01N33/53 G01N33/531 G01N33/543 G01N33/566 G01N33/573 G01N33/574 G01N33/577

CPC: Y10S435/962 Y10S435/967 Y10S435/975 Y10S436/813 G01N33/689 G01N33/57434 G01N2333/811 G01N2333/8121 G01N2800/342

European: G01N33/574C14 G01N33/68T S01N333/81B1

S01N333/81B1B S01N800/34B

US: 435/7.23 435/7.4 435/7.94 435/723 435/74 435/794 435/962 435/967 435/975 436/507 436/518 436/548 436/813 530/391.1

JP F-Term: 2G045 4H045 4H045/AA10 4H045/AA11 4H045/AA30 4H045/CA40 4H045/DA56 4H045/DA75 4H045/DA86 4H045/EA51 4C085 4C085/AA13 4C085/AA14 4C085/AA18 4C085/AA19 4C085/BB22 4C085/BB31 4C085/BB41 4C085/BB43 4C085/CC11 4C085/CC12 4C085/CC13 4C085/CC15 4C085/CC22 4C085/CC23 4C085/DD33 4C085/DD51 4C085/EE01

JP F-Index: C07K16/18 C07K19/00 G01N33/53/D G01N33/574/A A61K39/395/E A61K39/395/T G01N33/543/501/A G01N33/543/501/D G01N33/566

PatBase - US5599677_A

U.S. Patent

Feb. 4, 1997

Sheet 1 of 3

5,599,677

**Family:**

Publication number	Publication date	Application number	Application date
AT290212 E	20050315	AT19940906713T	19941222
AU199515187 A1	19950717	AU19950015187	19941222
CA2178504 AA	19960606	CA19942178504	19941222
CA2178504 C	20060905	CA19942178504	19941222
CA2546529 AA	19950706	CA19942546529	19941222
DE69434286 D1	20050407	DE19946034286	19941222
DE69434286 T2	20051229	DE19946034286T	19941222
EP0741868 A1	19961113	EP19950906713	19941222
EP0741868 B1	20050302	EP19950906713	19941222
ES2238678 T3	20050901	ES19950906713T	19941222
JP2004093563 A2	20040325	JP20030286450	20030805
JP3486413 B2	20040113	JP19950518164T	19941222
JP3833637 B2	20061018	JP20030286450	19941222
JP9508969 T2	19970909	JP19950518164T	19941222
US5599677 A	19970204	US19930174964	19931229
US5672480 A	19970930	US19950447576	19950523
WO9518381 A1	19950706	WO1994US14902	19941222

Priority:

US19930174964	19931229	CA19942178504	19941222	CA19942546529	19941222
JP19950518164	19941222	JP19950518164	19941222	JP19950518164T	19941222
JP19950518164T	19941222	WO1994US14902	19941222	US19950447576	19950523

Probable Assignee: ABBOTT LABORATORIES**Assignee(s):** (std): ABBOTT LAB**Assignee(s):** ABBOTT LABORATORIES ; ABBOTT LABORATORIES ABBOTT PARK ; ALEXANDER DEBRA B ; DOWELL BARRY L ; O MORCHOE SUSAN B ; KING CAROL A ; SMITH ALLAN H ; SMITH ALAN H**Inventor(s):** (std): DOWELL BARRY L ; KING CAROL A ; SMITH ALLAN H ; O MORCHOE SUSAN B ; SMITH ALAN H ; KING A ; O MORCHOE B ; DOWELL L ; SMITH H ; ALEXANDER B ; ALEXANDER DEBRA B**Inventor(s):** DEBRA B ALEXANDER ; CAROL A KING ; ALLAN H SMITH ; BARRY L DOWELL ; SUSAN B O MORCHOE**Agent(s):** OGILVY RENAULT LLP SENCRL SRL; KAWAGUCHI YOSHIO**Designated states:** AT AU BE CA CH DE DK ES FR GB GR IE IT JP LI LU MC NL PT SE

Title: METHODS AND APPARATUSES FOR PREDICTING RISK OF PROSTATE CANCER AND PROSTATE GLAND VOLUME

Abstract: Methods and apparatuses for predicting risk of prostate cancer and/or prostate gland volume are provided. More particularly, this disclosure relates to methods and apparatuses for providing the models and employing the models for predicting risk of prostate cancer and/or predicting prostate gland volume. The methods and apparatuses for predicting risk of prostate cancer and/or prostate gland volume are provided using, at least in part, information from a panel of kallikrein markers.

Classifications:

International (IPC 8-9): B01L B01L3/00 C12Q1/68 G01N33/48
G01N33/53 G01N33/543 G01N33/553 G01N33/574 G01N33/68
G01N37/00 G06F G06F19/00 G06F19/18 G06F19/24 G06F9/00 G06K9/00
G16B20/00 G16B25/00 G16B5/00 G16H G16H10/40 G16H50/20
G16H50/30 (Advanced/Invention);
B01L3/00 G06G7/48 (Advanced/Non-invention);
B01L G06F (Subclass/Invention)

CPC: G01N2800/50 G16H50/70 G16B40/20 B01L3/00 B01L3/502715
B01L2300/0654 B01L2300/0816 B01L2300/087 B01L2400/0487
B01L3/502 G16B20/00 G16B40/00 G16H10/40 G16H50/20 G16H50/30
G01N33/57434 B01L3/502761 C12Q1/6886 C12Q2600/112
C12Q2600/158 C12Q2600/16 G01N33/54366 G01N33/6893
G01N2333/96455

US: 1/1 422/69 435/287.2 435/7.4 506/9 702/21

JP F-Term: 2G045 4B050 4B050/DD11 4B050/LL03 2G045/AA26
2G045/CA25 2G045/DA36 2G045/FB03 2G045/HA09 2G045/JA01
2G045/JA07 2G058

JP F-Index: C12N9/50 G01N33/553 G01N33/574/A G01N33/48/Z
G01N33/53/D G01N33/543/521 G01N37/00/101

PatBase - US2013273643_AA




FIG. 1

Family:

Publication number	Publication date	Application number	Application date
AU2013230167 AA	20140925	AU20130230167	20130305
AU2013230167 BB	20180524	AU20130230167	20130305
AU2018203269 AA	20180531	AU20180203269	20180511
AU2018203269 BB	20200227	AU20180203269	20180511
BR112014021776 A2	20170620	BR20141121776	20130305
BR112014021776 A8	20170718	BR20141121776	20130305
CA2866007 AA	20140828	CA20132866007	20130305
CL2014002347 A1	20150327	CL20140002347	20140904
CN104364788 A	20150218	CN201380021939	20130305
CN104364788 B	20180206	CN201380021939	20130305
CN108108590 A	20180601	CN201810035218	20130305
CO7160023 A2	20150115	CO20140218469	20141002
DE202013012731 U1	20190314	DE201320012731U	20130305
EA030682 B1	20180928	EA20140000984	20130305
EA201400984 A2	20150430	EA20140000984	20130305
EA201890925 A2	20180928	EA20180090925	20130305
EA201890925 A3	20190131	EA20180090925	20130305
EP2823427 A2	20150114	EP20130710249	20130305
EP3312749 A1	20180425	EP20170187204	20130305
HK1206837 A1	20160115	HK20150107340	20150731
HK1206837 B	20190118	HK20150107340	20150731
HK1254684 A1	20190726	HK20180113665	20181025
ID201601386 A	20160318	ID2014P0005940	20130305

IL234462 A0	20141030	IL20130234462	20130305
JP2015512050 T2	20150423	JP20140561009T	20130305
JP2018109644 A2	20180712	JP20180045686	20180313
JP6308954 B2	20180411	JP20140561009T	20130305
JP6611844 B2	20191127	JP20180045686	20180313
KR101933752 B1	20181228	KR20147027992	20130305
KR20140140068 A	20141208	KR20147027992	20130305
KR20180030920 A	20180326	KR20187006233	20130305
MX2014010608 A1	20150511	MX20140010608	20130305
MX362555 B	20190124	MX20140010608	20130305
PE03332015 A1	20150325	PE20150000057	20130305
PE20150333 A1	20150325	PE20150000057	20130305
SG10201607357Y A1	20161028	SG20161007357	20130305
SG11201406213W A1	20141127	SG20141106213	20130305
TW201401094 A	20140101	TW20130107745	20130305
TW201732663 A	20170916	TW20170118157	20130305
TWI596494 B	20170821	TW20130107745	20130305
TWI638277 B	20181011	TW20170118157	20130305
US2013273643 AA	20131017	US20130785058	20130305
US2017091379 AA	20170330	US20160197148	20160629
US2017091380 AA	20170330	US20160197172	20160629
US2017168060 AA	20170615	US20170443102	20170227
US9672329 BB	20170606	US20130785058	20130305
WO13134179 A2	20130912	WO2013US28978	20130305

Priority:

FI20120005238	20120305	US20120606554P	20120305	AU20130230167	20130305
EP20130710249	20130305	CN201380021939	20130305	JP20140561009T	20130305
US20130785058	20130305	WO2013US28978	20130305	US20160197148	20160629
US20160197172	20160629	US20170443102	20170227	JP20180045686	20180313
AU20180203269	20180511				

Probable Assignee: OY ARCTIC PARTNERS AB

Assignee(s): (std): ARCTIC PARTNERS AB OY ; ARCTIC PARTNERS OY ; OPKO DIAGNOSTICS LLC ; LILJA HANS ; LINDER VINCENT ; OY ARCTIC PARTNERS AB ; STEINMILLER DAVID ; VICKERS ANDREW J ; SCARDINO PETER T

Assignee(s): OY ARCTIC PARTNERS ABYLIOPISTONKATU 2 H155FI-20100TURKUTURKUFI ; OPKO DIAGNOSTICS LLC3 - 4 CONSTITUTION WAYWOBOURNMA01801US ; OPKO DIAGNOSTICS

Inventor(s): (std): ANDREW J VICKERS ; DAVID STEINMILLER ; LILJA HANS ; LIJA HANS ; HANS LILJA ; SCARDINO PETER T ; LINDER VINCENT ; STEINMILLER DAVID ; VICKERS ANDREW J ; VINCENT LINDER ; VICKERS ANDREW J J ; PETER T SCARDINO ; SCARDINO PETER T T

Inventor(s): LILJA HANS LINDER ; T SCARDINO,PETER T. ; VINCENT ; VICKERS ANDREW JUS ; STEINMILLER DAVIDUS ; LILJA HANSUS ; SCARDINO PETER TUS ; LINDER VINCENTUS ; J VICKERS,ANDREW J.

Agent(s): SHELSTON IP; SHELSTON IP PTY LTD; CASSAN MACLEAN; CASSAN MACLEAN IP AGENCY INC; SARGENT AND KRAHN; MAURICIO JARAMILLO CAMPUZANO; HOFFMANN EITLE; CHINA PATENT AGENT HK LTD; GEORGE WIDJOJO AND PARTNERS; KAWABATA JUNICHI; YAMADA TAKUJI; TANAKA MITSUO; MARKS AND CLERK SINGAPORE LLP; WOLF GREENFIELD AND SACKS PC; LEE JESSAMINE N

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BN BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

10) Family number: 56547682 (US2015284804A)

© PatBase


Title: PROGNOSTIC METHOD FOR INDIVIDUALS WITH PROSTATE CANCER

Abstract: The present invention relates generally to the detection and identification of various forms of genetic markers, and various forms of proteins, which have the potential utility as diagnostic markers. By determining the level of a plurality of biomarkers and genetic markers in a patient sample, and combining the obtained values according to a predefined formula, it is possible to forecast if it is likely that the prostate cancer patient will require active therapy like radiation therapy or surgery. A method based on a redundantly designed combination of data is disclosed for estimating if prostate cancer is aggressive or indolent. Said method combines SNP data to form a composite value, wherein at least 5 percent of the SNPs can be disregarded.

Classifications:

International (IPC 8-9): C12M1/00 C12M1/34 C12Q1/68 C12Q1/6809
C12Q1/6827 C12Q1/6837 C12Q1/6886 C40B30/04 G01N27/62
G01N33/48 G01N33/53 G01N33/68 G06F19/24
G16B40/00 (Advanced/Invention)
CPC: C12Q1/6886 C12Q2600/118 C12Q2600/156 G16B40/00 G01N33/48
C12Q2600/16
US: 506/12 506/16 506/9 702/19
JP F-Term: 2G041 2G041/CA01 2G041/DA04 2G041/FA11 2G041/LA08
2G045 2G045/AA26 2G045/DA36 4B024 4B024/AA01 4B024/AA11
4B024/AA12 4B024/CA01 4B024/DA03 4B024/GA11 4B024/HA11
4B024/HA12 4B024/HA13 4B024/HA14 4B029 4B029/AA07 4B029/AA15
4B029/BB11 4B029/CC01 4B029/FA15 4B063 4B063/QA01 4B063/QA07
4B063/QA19 4B063/QQ04 4B063/QQ42 4B063/QQ52 4B063/QQ53
4B063/QR08 4B063/QS34 4B063/QX01 4B063/QX02
JP F-Index: C12M1/00/A C12N15/00/F C12N15/09/200 C12Q1/68/A
C12Q1/6886/C C12Q1/6886/Z G01N27/62/V G01N33/53/D G01N33/68

FIGURE 1

**Family:**

Publication number	Publication date	Application number	Application date
AU2013349721 AA	20150528	AU20130349721	20131120
AU2013349721 BB	20190328	AU20130349721	20131120
CA2891394 AA	20150513	CA20132891394	20131120
DE602013041732 D1	20180906	DE201360041732T	20131120
EP2922970 A1	20150930	EP20130799501	20131120
EP2922970 B1	20180808	EP20130799501	20131120
ES2694409 T3	20181220	ES20130799501T	20131120
JP2016508026 T2	20160317	JP20150542310T	20131120
RU2015124008 A	20170110	RU20150124008	20131120
RU2669809 C2	20181016	RU20150124008	20131120
US2015284804 AA	20151008	US20130443974	20131120
US2020010912 AA	20200109	US20190575940	20190919
US10428385 BB	20191001	US20130443974	20131120
WO14079874 A1	20140530	WO2013EP74270	20131120

Priority:

SE20120051310 20121120 SE20130050602 20130516 EP20130799501 20131120
 WO2013EP74270 20131120 US20150443974 20150519 US20190575940 20190919


Probable Assignee: PHADIA AB**Assignee(s):** (std): PHADIA AB ; PKHADIA AB**Assignee(s):** EKLUND MARTIN ; GRONBERG HENRIK**Inventor(s):** (std): GROENBERG HENRIK ; EKLUND MARTIN ; GRONBERG HENRIK ; GRENBERG KHENRIK**Agent(s):** SHELSTON IP; SHELSTON IP PTY LTD; RIDOUT AND MAYBEE LLP; BRANN AB; ELZABURU SLP ELZABURU SLP; AOYAMA TAMOTSU; MATSUTANI MICHIKO; YAMADA TAKUJI; YURIDICHESKAYA GORODISSKIY I PARTNER YOO FA; PORTER WRIGHT MORRIS AND ARTHUR LLP**Designated states:** AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BN BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IR IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW**11) Family number: 76313714 (KR20190121578A)**

© PatBase

Title: BIOMARKERS FOR DIAGNOSIS OF PROSTATE CANCER AND USES THEREOF

Abstract: The present invention relates to a biomarker for diagnosing prostate cancer and a usage thereof, and more specifically, to a composition for diagnosing prostate cancer comprising a specific miRNA or an agent for measuring expression level of a fragment of the same, to a kit for diagnosing prostate cancer containing the composition, and to a method for providing information for prostate cancer diagnosis including a step for measuring an expression level of the biomarker. The present invention identified a novel miRNA abnormally expressed in prostate cancer compared with normal tissues for the first time, and uses the same as a biomarker, thereby rapidly diagnosing prostate cancer in a non-invasive method without surgical procedure. Particularly, miRNA for diagnosing prostate cancer of the present invention has relatively large expression amount compared with other genes in a urine of an entity, thereby being able to be stably analyzed through qRT-PCR.

Classifications:**International (IPC 8-9):** C12Q1/6886 (Advanced/Invention)**CPC:** C12Q1/6886 C12Q2600/158 C12Q2600/178

**Family:**

Publication number	Publication date	Application number	Application date
KR102052398 B1	20191205	KR20180045062	20180418
KR20190121578 A	20191028	KR20180045062	20180418

Priority:

KR20180045062 20180418

Probable Assignee: NAT UNIV CHUNGBUK IND ACAD COOP FOUND**Assignee(s):** (std): CHUNGBUK NATIONAL UNIV IND ACADEMIC COOPERATION FOUNDATION ; NAT UNIV CHUNGBUK IND ACAD COOP FOUND**Assignee(s):** CHUNGBUK NATIONAL UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION**Inventor(s):** (std): KIM WUN JAE ; YUN SEOK JOONG ; BYUN YOUNG JOON ; JEONG PIL DU**12) Family number: 46421724 (US2010196207A)**

© PatBase

Title: STRUCTURES FOR CONTROLLING LIGHT INTERACTION WITH MICROFLUIDIC DEVICES


Abstract: Systems and methods for improved measurement of absorbance/transmission through fluidic systems are described. Specifically, in one set of embodiments, optical elements are fabricated on one side of a transparent fluidic device opposite a series of fluidic channels. The optical elements may guide incident light passing through the device such that most of the light is dispersed away from specific areas of the device, such as intervening portions between the fluidic channels. By decreasing the amount of light incident upon these intervening portions, the amount of noise in the detection signal can be decreased when using certain optical detection systems. In some embodiments, the optical elements comprise triangular grooves formed on or in a surface of the device. The draft angle of the triangular grooves may be chosen such that incident light normal to the surface of the device is redirected at an angle dependent upon the indices of refraction of the external medium (e.g., air) and the device material. Advantageously, certain optical elements described herein may be fabricated along with the fluidic channels of the device in one step, thereby reducing the costs of fabrication. Furthermore, in some cases the optical elements do not require alignment with a detector and, therefore, facilitate assembly and/or use by an end user.

Classifications:

International (IPC 8-9): A61J1/06 B01L B01L3/00 B29C45/00 G01N G01N15/06 G01N21/00 G01N21/01 G01N21/03 G01N21/05 G01N21/59 G01N21/76 G01N31/16 G01N33/00 G01N33/48 G01N33/53 G01N33/543 G01N33/545 G01N33/574 (Advanced/Invention); G01N21/05 (Advanced/Non-invention); B01L3/00 G01N21/00 G01N21/01 G01N21/03 (Core/Invention) **CPC:** C12Y304/21077 B01L3/502715 B01L2200/12 B01L2300/04 B01L2300/0627 B01L2300/0861 B01L2300/12 G01N33/53 G01N33/54366 G01N33/54373 G01N33/545 G01N33/57488 G01N2333/96455 B01L3/502707 B01L2300/0654 G01N21/0303 Y10T436/11 B01L3/5027 G01N21/59 **European:** B01L3/5027A G01N21/03A L01L300/06B6

US: 1/1 264/328.1 422/50 422/502 422/503 422/68.1 422/69 422/81 422/82.05 422/82.050S 422/82.07 422/82.08 422/82.09 422/82.090P 422/82.11 422/82.110S 435/283.1 435/287.2 435/288.7 436/164 436/172 436/43 506/18 506/39

PatBase - US2010196207_AA

**Family:**

Publication number	Publication date	Application number	Application date
DE202010018623 U1	20190117	DE201020018623U	20100202
DK2391451 T3	20181015	DK20100704614T	20100202
EP2391451 A1	20111207	EP20100704614	20100202

EP2391451 B1	20180912	EP20100704614	20100202
EP3278877 A1	20180207	EP20170178988	20100202
ES2695039 T3	20181228	ES20100704614T	20100202
HK1163591 A1	20120914	HK20120104127	20120426
HK1163591 B	20190823	HK20120104127	20120426
TR201815133 T4	20181121	TR20180015133T	20100202
US2010196207 AA	20100805	US20100698451	20100202
US2012237401 AA	20120920	US20120490055	20120606
US2013252321 AA	20130926	US20130898028	20130520
US2014308168 AA	20141016	US20140316069	20140626
US2015196908 A9	20150716	US20140316069	20140626
US2016305878 AA	20161020	US20160196922	20160629
US2016305937 AA	20161020	US20160196975	20160629
US2018085753 AA	20180329	US20170787078	20171018
US8221700 BB	20120717	US20100698451	20100202
US8480975 BB	20130709	US20120490055	20120606
US8802029 BB	20140812	US20130898028	20130520
US9770715 BB	20170926	US20140316069	20140626
US9827563 BB	20171128	US20160196922	20160629
US9827564 BB	20171128	US20160196975	20160629
WO10087999 A1	20100805	WO2010US00286	20100202

Priority:

US20090149253P 20090202 EP20100704614 20100202 US20100698451 20100202
WO2010US00286 20100202 US20120490055 20120606 US20130898028 20130520
US20140316069 20140626 US20160196922 20160629 US20160196975 20160629
US20170787078 20171018

Probable Assignee: OPKO DIAGNOSTICS LLC

Assignee(s): (std): CLAROS DIAGNOSTICS INC ; IOKO DIAGNOSTICS LLC ; LINDER VINCENT ; STEINMILLER DAVID ; OPKO DIAGNOSTICS LLC

Assignee(s): OPKO DIAGNOSTICS ; CLAROS DIAGNOSTICS LLC ; CLAROS MERGER SUBSIDIARY LLC UNDER NAME OF CLAROS ; CLAROS MERGER SUBSIDIARY LLC UNDER NAME OF CLAROS DIAGNOSTICS LLC

Inventor(s): (std): LINDER VINCENT ; STEINMILLER DAVID ; VINCENT LINDER ; DAVID STEINMILLER

Agent(s): HOFFMANN EITLE; PONS ANGEL; CLT PATENT AND TRADEMARK HK LTD; FULYA SUEMERALP; WOLF GREENFIELD AND SACKS PC; OYER TIMOTHY J

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PE PG PH PL PT RO RS RU SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

13) Family number: 28307824 (US2002123616A)

© PatBase

Title: PROSTATE SPECIFIC ANTIGEN (PSA) -PROTEINASE INHIBITORS COMPLEXES

Abstract: According to the method of the invention, immunoassays are applied to measure free PSA as well as a proteinase inhibitor complex. Free PSA and PSA complex are according to the invention measured by a non-competitive immunoassay employing at least two different monoclonal antibodies. The invention is further characterized by that the PSA proteinase inhibitor complex of interest is formed either with alpha 1 -antichymotrypsin, alpha 1 -protease inhibitor (API) or alpha 2 -macroglobulin. Moreover, the invention is characterized by that free PSA, the PSA-proteinase inhibitor complex and their ratio are applied in the diagnosis of patients with prostate cancer.

Classifications:

International (IPC 8-9): C12N15/02 C12P21/08 G01N33/53 G01N33/573

G01N33/574 G01N33/577 (Advanced/Invention);

G01N33/573 G01N33/574 (Core/Invention)

International (IPC 1-7): C07K16/18 C07K16/30 C12N15/06 C12N9/48

C12N9/64 C12N9/99 C12P21/08 C12Q1/37 G01N33/53 G01N33/543

G01N33/558 G01N33/566 G01N33/573 G01N33/574 G01N33/577

CPC: G01N33/573 G01N33/57438

European: G01N33/573 G01N33/574C16

US: 435/219 435/226 435/326 435/7.23 435/7.230S 436/501 436/514

436/518 530/350 530/387.7 530/387.700P 530/388.25 530/388.85

530/389.3

JP F-Term: 2G045 4B024 4B024/AA12 4B024/GA03 4B024/HA15 4B064

4B064/AG27 4B064/CA10 4B064/CA20 4B064/DA14

JP F-Index: C12N15/00/C C12P21/08 G01N33/53/D G01N33/574/A

G01N33/577/B




FIG. 1




FIG. 2

Family:

Publication number	Publication date	Application number	Application date
AT134448 E	19960315	AT19910913019T	19910722
DE0540573 T1	19950928	DE19910913019T	19910722
DE69117292 D1	19960328	DE19916017292	19910722
DE69117292 T2	19960718	DE19916017292T	19910722
DE69117292 T3	20040603	DE19916017292T	19910722
DE9117047 U1	19950629	DE19910017047U	19910722
DK0540573 T3	19960409	DK19910913019T	19910722
DK0540573 T4	20040405	DK19910913019T	19910722
EP0540573 A1	19930512	EP19910913019	19910722
EP0540573 B1	19960221	EP19910913019	19910722
EP0540573 B2	20031119	EP19910913019	19910722
ES2070107 T1	19950601	ES19910913019T	19910722
ES2070107 T3	19960416	ES19910913019T	19910722
ES2070107 T5	20040516	ES19910913019T	19910722
GR3019888 T3	19960831	GR19960401268T	19960513
JP2669566 B2	19971029	JP19910512776	19910722
JP6502719 T2	19940324	JP19910512776T	19910722
SE9002480 A0	19900723	SE19900002480	19900723
US2002123616 AA	20020905	US20010905998	20010717
US5501983 A	19960326	US19930956509	19930319
US5912158 A	19990615	US19950480708	19950607
US5939533 A	19990817	US19950446526	19950519
WO9201936 A1	19920206	WO1991FI00223	19910722

Priority:

SE19900002480 19900723	WO1991FI00223 19910722	US19930956509 19930319
US19950446526 19950519	US19990264176 19990305	US20010905998 20010717

Probable Assignee: STENMAN ULF HAAKAN

Assignee(s): (std): HANS LILJA ; LILJA HANS ; STENMAN ULF HAAKAN ; STENMAN ULF HAKAN ; ULF HAAKAN STENMAN

Assignee(s): STENMAN ULF HAAKAN GRANKULLA FI ; LILJA HANS HOELLVIKEN SE

Inventor(s): (std): STENMAN ULF HAAKAN ; STENMAN ULF HAKAN ; LILJA HANS

Inventor(s): LILJA HANS HOELLVIKEN SE ; ULF HAKAN STENMAN ; HANS LILJA ; ULF HAAKAN STENMAN ; STENMAN ULF HAAKAN GRANKULLA FI

Designated states: AT BE CH DE DK ES FR GB GR IT JP LI LU NL SE US

Title: METHOD FOR INDICATING THE PRESENCE OR NON-PRESENCE OF PROSTATE CANCER

Abstract: The present invention relates generally to the detection and identification of various forms of genetic markers, and various forms of proteins, which have the potential utility as diagnostic markers. By determining the level of a plurality of

biomarkers and genetic markers in a patient sample, and combining the obtained values according to a predefined formula, it is possible to determine if it is likely that the patient suffers from prostate cancer.

Classifications:

International (IPC 8-9): C12M1/34 C12N15/09 C12Q1/68 G01N27/62 G01N33/53 G01N33/574 G01N37/00 (Advanced/Invention)

CPC: G01N2333/96441 C12Q1/6886 C12Q2600/156 G01N33/57434


US: 435/6.11 506/16 506/9

JP F-Term: 2G041 2G041/CA01 2G041/DA04 2G041/EA01 2G041/FA11 2G041/FA12 2G041/JA07 2G041/LA08 2G045 2G058 4B024 4B024/AA12 4B024/CA01 4B024/CA09 4B024/HA11 4B029 4B029/AA07 4B029/BB15 4B029/BB20 4B029/FA15 4B063 4B063/QA17 4B063/QA19 4B063/QQ03 4B063/QQ42 4B063/QQ79 4B063/QR48 4B063/QR55 4B063/QS33 4B063/QS34 4B063/QX02

JP F-Index: C12M1/34/B C12N15/00/A C12Q1/68/A C12Q1/6886/C C12Q1/6886/Z G01N27/62/V G01N33/53/M G01N33/574/B G01N37/00/102

PatBase - US2015094221_AA

FIG. 1



Family:

Publication number	Publication date	Application number	Application date
AU2013263473 AA	20131121	AU20130263473	20130516
CA2871877 AA	20141028	CA20132871877	20130516
EP2850432 A2	20150325	EP20130727408	20130516
JP2015524052 T2	20150820	JP20150512606T	20130516
RU2014150777 A	20160710	RU20140150777	20130516
US2015094221 AA	20150402	US20130400298	20130516
WO13172779 A2	20131121	WO2013SE50554	20130516
WO13172779 A3	20140227	WO2013SE50554	20130516

Priority:

SE20120050508 20120516 SE20120051309 20121120 WO2013SE50554 20130516

Probable Assignee: PHADIA AB

Assignee(s): (std): PHADIA AB

Assignee(s): PHADIA ABBOX 6460S-751 37UPPSALASE ; EKLUND MARTIN ; GRONBERG HENRIK

Inventor(s): (std): GROENBERG HENRIK ; EKLUND MARTIN ; GRONBERG HENRIK

Inventor(s): EKLUND MARTINSE ; GRONBERG HENRIKSE

Agent(s): SHELSTON IP; SHELSTON IP PTY LTD; RIDOUT AND MAYBEE LLP; BRANN AB; TANAKA MITSUO; YAMAZAKI HIROSHI

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BN BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW

15) Family number: 30053898 (US2003059864A)

© PatBase


Title: METHOD OF ANALYZING NON-COMPLEXED FORMS OF PROSTATE SPECIFIC ANTIGEN IN A SAMPLE TO IMPROVE PROSTATE CANCER DETECTION

Abstract: Assays for detecting and determining the presence of prostate cancer is provided. The assays are capable of detecting prostate cancer in the population of men with a significantly higher ratio of free PSA to total PSA. The assays are also capable of detecting prostate cancer in the population of men with a low amount of total PSA, i.e., in the range of 2 to 4 ng/ml. In accordance with one embodiment of the present invention, the assay includes the steps of (a) determining the amount of total PSA contained in a biological sample from the patient, (b) determining the amount of free PSA in the sample; and calculating the ratio of the free PSA to the total PSA, (c) determining the amount of pPSA in the sample, (d) determining the amount of BPSA in the sample, (e) determining the amount of inPSA in the sample, and (f) correlating the amount of inPSA contained in the sample to the presence of prostate cancer in the patient by comparing the amount of inPSA to a predetermined value established with control samples of known cancer and benign disease diagnosis, based on both the level of total PSA and the percent free PSA.

Classifications:

International (IPC 8-9): A61K35/12 A61K48/00 C07K16/32 C07K16/40

C12N15/02 C12N5/10 C12N5/12 C12N9/64 C12P21/08 G01N33/53
G01N33/532 G01N33/573 G01N33/574 G01N33/577
G01N33/68 (Advanced/Invention);
A61K35/12 A61K48/00 C07K16/40 C12N15/02 C12N5/10 C12P21/08
C12R1/91 G01N33/532 G01N33/573 G01N33/577 (Advanced/Non-invention);
C07K16/40 C12N15/02 C12N5/10 C12N9/64 C12P21/08 G01N33/532
G01N33/573 G01N33/574 G01N33/577 (Core/Invention);
A61K35/12 A61K48/00 (Core/Non-invention)
International (IPC 1-7): A61K4/900 A61K49/00 C07H21/04 C07K16/30
C07K16/32 C07K16/40 C12N15/02 C12N5/06 C12N5/10 C12N5/12
C12N9/00 C12N9/64 C12P21/02 C12P21/08 C12Q1/00 C12Q1/68
G01N33/348 G01N33/353 G01N33/3567 G01N33/3574 G01N33/48 G01N33/50
G01N33/53 G01N33/532 G01N33/567 G01N33/573 G01N33/574
G01N33/577 G01N33/68 G06F19/00
CPC: Y10S435/96 Y10S435/975 Y10S436/811 Y10S436/813 A61K35/12
A61K48/00 C12N9/6445 Y10T436/25 G01N33/57434
European: C12N9/64F21K G01N33/574C14 K61K35/12 K61K48/00
M12N203/02 M12N209/00 M12N215/00
US: 424/9.1 424/91 435/183 435/183S 435/320.1 435/320.100S 435/325
435/325S 435/4 435/41 435/6 435/6.14 435/6.140P 435/69.3
435/69.300S 435/6P 435/7.1 435/7.2 435/7.21 435/7.23 435/7.230P
435/7.230S 435/7.92 435/70.1 435/70.21 435/701 435/72 435/721
435/723 435/792 435/960 435/975 436/174 436/63 436/64 436/811
436/813 530/300 530/350 530/386 530/387.1 530/387.7 530/387.9
530/388.1 530/388.15 530/388.26 530/388.260S 536/23.2 536/23.200S
702/19 702/19S
JP F-Term: 2G045 4B024 4B024/AA12 4B024/BA44 4B024/GA03
4B024/HA15 4B050 4B050/CC03 4B050/DD11 4B050/LL03 4B064
4B064/AG27 4B064/CA10 4B064/CA20 4B064/CC24 4B064/DA14 4B065
4B065/AA92 4B065/AB05 4B065/AC14 4B065/BA08 4B065/CA25
4B065/CA46 4H045 4H045/AA11 4H045/AA30 4H045/BA10 4H045/CA40
4H045/DA75 4H045/DA76 4H045/DA86 4H045/DA89 4H045/EA51
4H045/FA74 4H045/AA20 4H045/CA41 4H045/FA71 4H045/GA22
4H045/GA23 4H045/GA26
JP F-Index: C07K16/40 C12N15/00/C C12N5/00/B C12N5/00/102
C12N5/20 C12N9/64/ZNA/A C12P21/08 G01N33/573/A G01N33/577/B
G01N33/532/A G01N33/574/A C07K16/32/ZNA



Family:

Publication number	Publication date	Application number	Application date
AT308756 E	20051115	AT20000922118T	20000412
AU200042187 A1	20001117	AU20000042187	20000407
AU200042187 A5	20001117	AU20000042187D	20000407
AU200042354 A1	20001117	AU20000042354	20000412
AU200042354 A5	20001117	AU20000042354D	20000412
AU776578 B2	20040916	AU20000042354	20000412
AU780458 B2	20050324	AU20000042187	20000407
CA2370290 AA	20011024	CA20002370290	20000412
CA2370290 C	20120117	CA20002370290	20000412
CA2371577 AA	20011024	CA20002371577	20000407
CN1656231 A	20050817	CN20038011904	20030522
CN1656379 A	20050817	CN20038011902	20030522
DE60023683 D1	20051208	DE20006023683	20000412
DE60023683 D1	20051208	DE20006023683T	20000412
DE60023683 T2	20060601	DE20006023683T	20000412
EP1173556 A1	20020123	EP20000921930	20000407
EP1175619 A1	20020130	EP20000922118	20000412
EP1175619 B1	20051102	EP20000922118	20000412
EP1506401 A2	20050216	EP20030755428	20030522
EP1506401 A4	20060823	EP20030755428	20030522
EP1546360 A2	20050629	EP20030755432	20030522
EP1546360 A4	20060322	EP20030755432	20030522
JP2002542820 T2	20021217	JP20000615743T	20000407
JP2002543431 T2	20021217	JP20000615817T	20000412
JP2005527828 T2	20050915	JP20040508248T	20030522
JP2006508332 T2	20060309	JP20040507519T	20030522
JP4447796 B2	20100407	JP20000615817T	20000412
US2003059864 AA	20030327	US20020246582	20020918
US2003119033 AA	20030626	US20020252862	20020924
US2003219840 AA	20031127	US20020154715	20020524
US6423503 BA	20020723	US19990303339	19990430
US6482599 BA	20021119	US19990303208	19990430
US7211397 BB	20070501	US20020246582	20020918
WO0066718 A1	20001109	WO2000US09415	20000407
WO0067030 A1	20001109	WO2000US09789	20000412
WO03100006 A2	20031204	WO2003US16155	20030522
WO03100006 A3	20050303	WO2003US16155	20030522
WO03100079 A2	20031204	WO2003US16148	20030522
WO03100079 A3	20040923	WO2003US16148	20030522

Priority:

US19990303208	19990430	US19990303339	19990430	WO2000US09415	20000407
WO2000US09789	20000412	US20020154715	20020524	US20020246582	20020918

Assignee(s): (std): BAYLOR COLLEGE MEDICINE ; BAYLOR COLLEGE OF MEDECINE ; BAYLOR COLLEGE OF MEDICINE ; HYBRITECH INC ; MIKOLAJCZYK STEPHEN D ; HYBRITECH INC AND BAYLOR COLLEGE ; BECKMAN COULTER INC ; RITTENHOUSE HARRY G

Assignee(s): SLAWIN KEVIN ; WANG TANG J ; WOLFERT ROBERT L ; WOLFERT ROBERT ; RITTENHOUSE HARRY ; WANG TANG ; HYBRITECH INC AND BAYLOR COLLEGE OF MEDICINE ; BECKMAN COULTER INC WAS BECKMAN INSTRUMENTS INC ; MIKOLAJCZYK STEPHEN ; BAYLOR COLLEGE OF MEDICINE TEXAS MEDICAL CENTER ; HYBRITECH INC AND BAYLOR COLLEGE OF MEDIC ; HYBRITECH INC SAN DIEGO ; BAYLOR COLLEGE OF MEDICINE HOUSTON

Inventor(s): (std): HARRY RITTENHOUSE ; MIKOLAJCZYK STEPHEN ; RITTENHOUSE HARRY ; MIKOLAJCZYK STEPHEN D ; KEVIN SLAWIN ; SLAWIN KEVIN ; RITTENHOUSE HARRY G ; TANG WANG ; STEPHEN MIKOLAJCZYK ; ROBERT WOLFERT ; WANG TANG ; WOLFERT ROBERT ; WANG TANG JANG ; WOLFERT ROBERT L ; WANG TANG J

Inventor(s): HARRY G RITTENHOUSE ; STEPHEN D MIKOLAJCZYK ; TANG JANG WANG ; ROBERT L WOLFERT

Agent(s): RYOTARO IP PTY LTD ; SHELSTON IP ; MACRAE AND CO ; MATSUNAGA NOBUYUKI ; OGOU SOICHI ; SATO RYOTARO ; WILLIAM H MAY ; D DAVID HILL ; HOGAN AND HARTSON LLP

Designated states: AT AU BE BG CA CH CN CY CZ DE DK EE ES FI FR GB GR HU IE IT JP LI LU MC NL PT RO SE SI SK TR

16) Family number: 60461981 (US2016025732A)


© PatBase

Title: COMPOSITIONS AND METHODS RELATED TO DIAGNOSIS OF PROSTATE CANCER

Abstract: Aspects of the disclosure relate to improved methods for predicting whether a prostate tissue biopsy obtained from a subject will contain detectable prostate cancer.

Classifications:

International (IPC 8-9): A61K A61K35/52 A61K39/00 G01N G01N33/00 G01N33/48 G01N33/53 G01N33/543 G01N33/574 G01N33/68 G01N37/00 G06F G06F19/00 G06F19/10 G06F19/18 G06F19/24 G06N7/00 G06Q50/22 G16B20/00 G16B25/10 G16B5/00 G16H50/20 (Advanced/Invention); G01N (Subclass/Invention)
CPC: G06N7/005 G16B20/00 G16B40/00 Y02A90/26 G01N33/57434 G01N2333/96455 G16H50/20
US: 1/1 435/7.4 435/7.93 506/9 702/19
JP F-Term: 2G045 2G058 5L099 5L099/AA04 2G045/AA26 2G045/CA25 2G045/CA26 2G045/DA36 2G045/JA01
JP F-Index: G01N33/543/501/D G01N33/543/501/H G01N33/543/501/M G01N33/543/575 G01N33/574/A G01N33/574/B G01N37/00/101 G06Q50/22 G16H20/00 G16H50/00 G01N33/48/Z



Family:

Publication number	Publication date	Application number	Application date
AR099883 AA	20160824	AR2015P100936	20150330
AU2015237270 AA	20161020	AU20150237270	20150327
AU2016254127 AA	20171026	AU20160254127	20160429
BR112016022407 A2	20171212	BR20161122407	20150327
BR112017022391 A2	20180710	BR20171122391	20160429
CA2944001 AA	20160926	CA20152944001	20150327
CA2982262 AA	20171006	CA20162982262	20160429
CL2016002419 A1	20170331	CL20160002419	20160927
CL2017002701 A1	20180706	CL20170002701	20171025
CN106663149 A	20170510	CN201580027646	20150327
CN107530412 A	20180102	CN201680025917	20160429
CO20160003548 A2	20170410	CO20160003548	20161028
CO20170010808 A2	20180419	CO20170010808	20171024
DE202015009668 U1	20190321	DE201520009668U	20150327
DE202016008673 U1	20190228	DE201620008673U	20160429
EA201691952 A1	20170531	EA20160091952	20150327
EA201792372 A1	20180330	EA20170092372	20160429
EP3123381 A1	20170201	EP20150768735	20150327
EP3123381 A4	20180221	EP20150768735	20150327
EP3247387 A1	20171129	EP20160787201	20160429
EP3247387 A4	20180912	EP20160787201	20160429
EP3287786 A2	20180228	EP20170187202	20160429
EP3287786 A3	20180321	EP20170187202	20160429
EP3299977 A1	20180328	EP20170187203	20150327

HK1234177 A1	20180209	HK20170107622	20170801
HK1247559 A1	20180928	HK20180107008	20180529
HK1247824 A1	20181005	HK20180107259	20180604
ID201712048 A	20171103	ID2016P0007212	20150327
ID201806309 A	20180629	ID2017PID08389	20160429
IL247981 A0	20161130	IL20150247981	20150327
IL254833 A0	20171231	IL20160254833	20160429
JP2017515127 T2	20170608	JP20170502945T	20150327
JP2018518661 T2	20180712	JP20170556721T	20160429
KR20170008729 A	20170124	KR20167030100	20150327
KR20180018514 A	20180221	KR20177034395	20160429
MX2016012667 A1	20170109	MX20160012667	20150327
MX2017013881 A1	20180312	MX20170013881	20160429
PE02982017 A1	20170418	PE20160001817	20150327
PE09302018 A1	20180608	PE20180000345	20160429
PE20170298 A1	20170418	PE20160001817	20150327
SG10201808585T A1	20181129	SG20181008585	20150327
SG10201909984T A1	20191230	SG20191009984	20160429
SG11201608035U A1	20161028	SG20161108035	20150327
SG11201708289T A1	20171129	SG20171108289	20160429
TW201621320 A	20160616	TW20150110105	20150327
TW201705028 A	20170201	TW20160113583	20160429
TWI687688 B	20200311	TW20150110105	20150327
US2016025732 AA	20160128	US20150671355	20150327
US2016320394 AA	20161103	US20160143329	20160429
US2017089904 AA	20170330	US20160143345	20160429
WO15148979 A1	20151001	WO2015US23096	20150327
WO15148979 A8	20160107	WO2015US23096	20150327
WO16176529 A1	20161103	WO2016US29959	20160429

Priority:

US20140972099P	20140328	EP20150768735	20150327	US20150671355	20150327
WO2015US23096	20150327	US20150154616P	20150429	EP20160787201	20160429
US20160143329	20160429	US20160143345	20160429	WO2016US29959	20160429

Probable Assignee: OPKO DIAGNOSTICS LLC

Assignee(s): (std): OPKO DIAGNOSTICS LLC

Assignee(s): PETERSSON KIM ; SCARDINO PETER T ; STEINMILLER DAVID ; VICKERS ANDREW J ; SJOBERG DANIEL ; DONG YAN ; LILJA HANS ; LINDER VINCENT ; LOVGREN TIMO ; OPKO DIAGNOSTICS

Inventor(s): (std): SCARDINO PETER T ; VICKERS ANDREW J ; LINDER VINCENT ; LOVGREN TIMO ; LILJA HANS ; PETERSSON KIM ; STEINMILLER DAVID ; HANS LILJA ; ANDREW J VICKERS ; TIMO LOVGREN ; KIM PETERSSON ; PETER T SCARDINO ; DAVID STEINMILLER ; VINCENT LINDER ; YAN DONG ; DANIEL SJOBERG ; DONG YAN ; SJOBERG DANIEL

Inventor(s): SCARDINO ; PETER SCARDINO T ; ANDREW VICKERS J

Agent(s): SHELSTON IP PTY LTD; CASSAN MACLEAN; CASSAN MACLEAN IP AGENCY INC; SARGENT AND KRAHN; ESTUDIO CAREY LTDA; JOSE ANDRES RINCON USCATEGUI; HOFFMANN EITLE; HONG KONG UNITALEN INTELLECTUAL PROPERTY AGENCY LTD; CHINA PATENT AGENT HK LTD; GEORGE WIDJOJO SH; KAWABATA JUNICHI; YAMADA TAKUJI; TANAKA MITSUO; TOMITA KENJI; MARKS AND CLERK SINGAPORE LLP; YOUNG DANIEL W; LEE JESSAMINE N

Designated states: AE AG AL AM AO AT AU AZ BA BB BE BF BG BH BJ BN BR BW BY BZ CA CF CG CH CI CL CM CN CO CR CU CY CZ DE DK DM DO DZ EC EE EG ES FI FR GA GB GD GE GH GM GN GQ GR GT GW HN HR HU ID IE IL IN IR IS IT JP KE KG KM KN KP KR KZ LA LC LI LK LR LS LT LU LV LY MA MC MD ME MG MK ML MN MR MT MW MX MY MZ NA NE NG NI NL NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SI SK SL SM SN ST SV SY SZ TD TG TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW